Home › Funds › Patient Square Capital LP › RCUS
Patient Square Capital LP position in RCUS
ARCUS BIOSCIENCES INC · Health Care
Patient Square Capital LP reported holding 410,000 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$10.6M, representing 1.69% of its reported portfolio and ranking #15 among its reported holdings. Patient Square Capital LP has disclosed RCUS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Patient Square Capital LP's RCUS position evolved
Patient Square Capital LP first disclosed a stake in RCUS in Q4 2025 at 170,000 shares (US$4.1M). The position peaked in Q2 2026 at 355,800 shares, worth US$11.0M. Across 4 filings, Patient Square Capital LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 410,000 shares valued at US$10.6M — an increase of 54,200 shares quarter over quarter.. Notable position changes include a 82% increase in Q2 2026 (shares fell 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 170.00K | $4.05M | New |
| Q1 2026 | 195.00K | $4.21M | Add |
| Q2 2026 | 355.80K | $10.97M | Add |
| Q3 2026 | 410.00K | $10.59M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCUS and 13F data
RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 47 other funds we track also report a position in RCUS — the largest reported positions include GILEAD SCIENCES, INC. (US$811.7M), MONTANOVA CAPITAL, LLC (US$147.3M), Siren, L.L.C. (US$62.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCUS
- GILEAD SCIENCES, INC. 31.42M sh · $811.70M · Q3 2026
- MONTANOVA CAPITAL, LLC 4.78M sh · $147.26M · Q2 2026
- Siren, L.L.C. 2.42M sh · $62.52M · Q3 2026
- SAMLYN CAPITAL, LLC 1.55M sh · $47.70M · Q2 2026
- Soleus Capital Management, L.P. 1.17M sh · $36.03M · Q2 2026
- Sofinnova Investments, Inc. 945.69K sh · $29.16M · Q2 2026
- Parkman Healthcare Partners LLC 919.27K sh · $28.34M · Q2 2026
- BAKER BROS. ADVISORS LP 844.82K sh · $26.05M · Q2 2026
- Logos Global Management LP 650.00K sh · $20.04M · Q2 2026
- Ikarian Capital, LLC 504.56K sh · $15.56M · Q2 2026
- Decheng Capital LLC 464.78K sh · $14.33M · Q2 2026
- DAFNA Capital Management LLC 441.83K sh · $13.62M · Q2 2026
More on Patient Square Capital LP
FAQ
How long has Patient Square Capital LP held RCUS?
Patient Square Capital LP has disclosed RCUS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Patient Square Capital LP's current position in RCUS?
As of Q3 2026, Patient Square Capital LP holds 410.00K shares of RCUS (ARCUS BIOSCIENCES INC), valued at $10.59M, representing 1.69% of its reported portfolio and ranking #15.
Has Patient Square Capital LP been buying or selling RCUS?
In the latest 13F filing (Q3 2026), Patient Square Capital LP increased its position in RCUS. The position peaked in Q2 2026 at 355.80K shares.
Which other funds hold RCUS?
Other major institutional holders of RCUS include GILEAD SCIENCES, INC., MONTANOVA CAPITAL, LLC, Siren, L.L.C., among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.